US-based Zydus Pharmaceuticals, leading arm of Zydus Cadila, has announced that it has got final sanction from the US Food and Drug Administration (USFDA) to sell Ramipril tablets.

The approval has been granted for the tablets in potencies of 1.25 mg, 2.5 mg, 5 mg and 10 mg.

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor, which is indicated in the treatment of hypertension as well as congestive heart failure.

Cadila Healthcare is the parent company of the Zydus Cadila group. The group is involved in pharmaceuticals, diagnostics, herbal products, skin care products as well as OTC products.

Stock of Cadila Healthcare Ltd settled the day at Rs 517, up 2.38% on Bombay Stock Exchange (BSE).